Privia Health Group CFO Sells Over $100K in Shares
Privia Health Group's CFO, David Mountcastle, sold 5,566 shares of company stock for over $116,000, reducing his position by 2.53%. This recent sale contributes to a total of over $800,000 in stock sales by Mountcastle in recent months, raising questions among investors about the company's financial outlook. Investors are advised to closely monitor future insider trading activity and the company's upcoming earnings report.
Privia Health Group (NASDAQ:PRVA) CFO David Mountcastle Sells 5,566 Shares
Privia Health Group's CFO, David Mountcastle, sold 5,566 shares of PRVA on April 2nd at $20.85 per share, reducing his ownership by 2.53%. This recent sale is part of a series of transactions since late February, totaling over 49,000 shares. Despite the insider selling, PRVA shares traded up 1.8% to $21.59, following strong quarterly earnings that beat analyst expectations.
Privia Health (PRVA) CFO sells shares to cover RSU tax obligations
Privia Health's EVP & CFO, David Mountcastle, sold 5,566 shares of common stock at $20.85 per share on April 2, 2026. This transaction was a "sell to cover" to satisfy tax obligations from vesting restricted stock units (RSUs), not a discretionary sale. After the sale, Mountcastle directly holds 214,847 shares and indirectly holds an additional 8,695 shares through his spouse.
Truist Financial Maintains Privia Health(PRVA.US) With Buy Rating, Cuts Target Price to $21.21
Truist Financial has reiterated its Buy rating for Privia Health (PRVA.US) stock. However, the firm has also reduced its target price for Privia Health to $21.21.
Truist reiterates Buy on Privia Health stock after investor meetings By Investing.com
Truist Securities has reiterated a Buy rating and a $33.00 price target for Privia Health Group Inc. following investor meetings. The firm expressed increased confidence in Privia Health's growth model, citing disciplined geographic expansion, provider conversion, and strong cash generation, supported by robust financial results including 22% revenue growth and $163 million in free cash flow over the last twelve months. Analysts view Privia Health's model as differentiated within value-based care, with favorable long-term prospects.
Truist reiterates Buy on Privia Health stock after investor meetings By Investing.com
Truist Securities reiterated a Buy rating and a $33.00 price target for Privia Health Group Inc (NASDAQ:PRVA) after investor meetings. The firm cited increased confidence in the company's growth model, strong free cash flow conversion, net-cash balance sheet, and disciplined capital allocation. Other analysts like Piper Sandler and Jefferies also raised their price targets following Privia Health's strong Q4 2025 financial results.
PRVA PE Ratio & Valuation, Is PRVA Overvalued
Privia Health Group Inc (PRVA) is currently in the "Fair zone" according to its forward PS ratio of 0.99, which is considerably lower than its five-year average of 47.35. Its fair price is estimated to be between $20.56 and $50.84 based on relative valuation. However, PRVA's P/S ratio of 1.00 is significantly above the industry average of 0.66, suggesting the premium might be unsustainable despite robust revenue growth.
PRVA Technical Analysis & Stock Price Forecast
This article provides a technical analysis of Privia Health Group Inc (PRVA), indicating a "Strong Sell" consensus based on various technical indicators and moving averages. Key metrics like MACD and multiple simple moving averages suggest a bearish outlook, with the stock trading below essential long-term averages. The analysis also outlines critical support and resistance levels for investors to monitor.
Privia Health Group, Inc. (NASDAQ:PRVA) Given Consensus Rating of "Moderate Buy" by Analysts
Privia Health Group, Inc. (NASDAQ:PRVA) has received a consensus "Moderate Buy" rating from analysts, with an average 12-month price target of $31.13. The company recently surpassed earnings and revenue expectations, reporting $0.25 EPS versus $0.04 expected and $541.17 million in revenue, a 17.4% year-over-year increase. Despite analyst optimism, insider selling, totaling approximately $5.52 million in the past three months, presents a note of caution, though insiders still hold about 10.7% of shares.
David Mountcastle reports multiple PRVA share sales (NASDAQ: PRVA)
David Mountcastle filed a Form 144 detailing proposed sales of Privia Health Group, Inc. (PRVA) Common Stock. The filing includes several open-market dispositions in February and March 2026, alongside a restricted stock vesting on April 1, 2026. Specific sales cited include 5,361 shares for $134,030.87 on February 26, 2026, and 7,697 shares for $192,798.08 on February 27, 2026, with further sales exceeding 5,000 shares each in March.
Privia Health partners with Integrated Medical Services to expand in Arizona
Privia Health has announced a new partnership with Integrated Medical Services (IMS) to expand its footprint in Arizona. This collaboration aims to enhance healthcare services and access for patients in the region. The partnership signifies Privia Health's strategic growth initiatives and commitment to strengthening its integrated care network.
PRVA SEC Filings - Privia Health Group, Inc. 10-K, 10-Q, 8-K Forms
This page provides access to Privia Health Group, Inc. (PRVA) SEC filings, including 10-K, 10-Q, and 8-K reports, which detail the company's financial condition, operations, and material events. The platform offers AI-powered summaries and sentiment analysis for these documents to help investors analyze information efficiently. Recent filings highlight a Rubicon-linked group's disclosed stake and Privia Health's Q2 2025 financial results, showing revenue growth and strategic acquisitions.
PRVA SEC Filings - Privia Health Group, Inc. 10-K, 10-Q, 8-K Forms
This article provides a comprehensive overview of Privia Health Group, Inc. (PRVA) SEC filings, including 10-K, 10-Q, and 8-K forms, designed for investors and traders. It details the company's financial condition, operations, and governance, highlighting key disclosures such as quarterly results and significant corporate events. The platform also offers AI-powered summaries for lengthy documents and insights into insider trading activities.
A Look At Privia Health Group (PRVA) Valuation After Recent Share Price Pressure
Privia Health Group (PRVA) has experienced recent share price pressure, showing negative returns over the past month and three months. Despite this, valuation models from Simply Wall St suggest the stock is significantly undervalued, with a fair value estimate of $31.85 and a discounted cash flow model indicating a value of $42.82 against its current price of $20.02. The article attributes this potential undervaluation to the company's growth in value-based care and expanding margins, while acknowledging risks like rising labor costs and stricter regulations.
Vanguard disaggregates holdings, reports 0% stake in Privia Health (PRVA)
The Vanguard Group filed an amended Schedule 13G/A, reporting 0 shares and 0% beneficial ownership of Privia Health common stock. This change is due to an internal realignment on January 12, 2026, which led to certain Vanguard subsidiaries reporting their beneficial ownership separately. The filing clarifies that Vanguard itself no longer beneficially owns the securities held by these disaggregated entities.
Riverbridge Partners LLC Sells 50,277 Shares of Privia Health Group, Inc. $PRVA
Riverbridge Partners LLC reduced its stake in Privia Health Group, Inc. by 1.1% in Q4, selling 50,277 shares, though it remains its 10th largest holding. Despite recent insider selling by the CFO and EVP, analysts maintain a "Moderate Buy" rating with an average target price significantly higher than the current trading price. Privia Health Group also recently exceeded Q4 earnings and revenue estimates.
PRVA SEC Filings - Privia Health Group, Inc. 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Privia Health Group (PRVA) SEC filings, including 10-K, 10-Q, 8-K forms, and insider trading documents. It details the company's financial condition, operations, and governance, with AI-powered summaries to highlight key information and changes over time. Recent filings cover insider sales, option exercises, and strong 2025 financial results with positive 2026 guidance.
Privia Health Group (NASDAQ:PRVA) Given New $25.00 Price Target at Barclays
Barclays has increased its price target for Privia Health Group (NASDAQ:PRVA) to $25.00 from $23.00, maintaining an "equal weight" rating, suggesting an 18.32% potential upside from its previous close. This recalibration follows Privia Health Group's recent strong earnings report, where it surpassed analyst expectations with an EPS of $0.25 against an estimated $0.04 and revenues of $541.17 million. Overall analyst sentiment for PRVA remains positive, with a consensus "Moderate Buy" rating and an average price target of $31.13.
Privia Health Earns 2026 HFMA MAP Award for Revenue Cycle Excellence
Privia Health Group, Inc. announced that its affiliated medical groups received the 2026 HFMA MAP Award for High Performance in Revenue Cycle. This marks the ninth time in ten years Privia Health has been recognized for its revenue cycle capabilities, attributed to advanced analytics, AI-enabled automation, enhanced provider engagement, and scalable operating models. The award acknowledges Privia Health's sustained excellence in key revenue cycle metrics and its commitment to patient-centered best practices.
Privia Health’s billing operation earns HFMA honor 9 times in 10 years
Privia Health (Nasdaq: PRVA) has received the 2026 HFMA MAP Award for High Performance in Revenue Cycle, marking its ninth recognition in the last ten years. This award acknowledges the company's sustained excellence across key revenue cycle metrics, driven by advanced analytics, AI automation, enhanced provider engagement, and scalable operating models. The company's Senior Vice President, Melanie Suranto, highlighted that this consistent recognition underscores the strength of their revenue cycle operations and commitment to a patient-centered financial experience.
Privia Health Group CFO Sells $283,000 Worth of Shares to Cover Taxes
Privia Health Group's CFO, David Mountcastle, sold 13,018 shares for approximately $283,000 between March 12 and 13, 2026, to cover tax withholding obligations resulting from vested performance stock units. This transaction reduced his direct holdings by 5.24% but is not seen as an indicator for investing decisions since it was tax-related. The company recently exceeded earnings expectations for Q4 FY 2025 and is optimistic about its acquisition of an Accountable Care Organization.
How Privia Health Group Inc. (PRVA) Affects Rotational Strategy Timing
This article analyzes Privia Health Group Inc. (PRVA) using AI models to determine its effect on rotational strategy timing. It presents key findings such as neutral near-term sentiment, a strong risk-reward setup, and offers three distinct institutional trading strategies: Position Trading, Momentum Breakout, and Risk Hedging. The analysis also includes multi-timeframe signal analysis with support and resistance levels.
Implied volatility surging for Privia Health stock options
This article indicates that the implied volatility for Privia Health stock options has been increasing. This suggests that the market expects larger price swings for PVH shares in the near future.
Piper Sandler reiterates Privia Health stock rating on MSSP analysis
Piper Sandler reiterated an Overweight rating and a $36.00 price target for Privia Health Group Inc. (NASDAQ:PRVA) after analyzing its MSSP data, noting the company's strong adjusted EBITDA growth of 38.7% in 2025 and diverse profitability sources. The firm believes capital deployment could accelerate Privia Health's EBITDA CAGR beyond current estimates, with the price target suggesting a 66.7% upside. This follows Privia Health's impressive Q4 2025 results, which exceeded EPS and revenue forecasts, leading other analysts like Jefferies and Citizens to also maintain positive outlooks.
PRVA - Privia Health Group, Inc. Latest Stock News & Market Updates
This page provides news and analysis for Privia Health Group (PRVA), a technology-driven physician enablement company. It details the company's financial results, acquisitions, and expansions, as well as its performance in value-based care programs like the Medicare Shared Savings Program. The article highlights key metrics investors should follow and recent corporate developments.
Insider Selling: Privia Health Group (NASDAQ:PRVA) CFO Sells 6,391 Shares of Stock
Privia Health Group's (NASDAQ:PRVA) CFO, David Mountcastle, sold 6,391 shares of company stock for over $141,305 on March 16th, adding to several sales since late February. This transaction reduced his stake by 2.82%, contributing to a 2.3% share price dip to $21.59. Despite the insider selling, analysts maintain a "Moderate Buy" rating with an average $31 price target, reflecting strong recent earnings that surpassed expectations.
Insider Selling: Privia Health Group (NASDAQ:PRVA) CEO Sells 26,509 Shares of Stock
Privia Health Group (NASDAQ:PRVA) CEO Parth Mehrotra recently sold 26,509 shares of the company's stock for over $586,000, part of a larger sale of 165,037 shares totaling approximately $3.69 million between March 6th and 16th. These sales reduced his ownership by 4.56%. Despite the insider selling and a 2.3% dip in stock price post-filings, Privia Health Group recently exceeded quarterly earnings estimates, and analysts maintain a "Moderate Buy" rating with an average price target of $31.
Privia Health (NASDAQ: PRVA) CEO sells 26,509 shares for tax withholding
Privia Health Group Inc. CEO Parth Mehrotra sold 26,509 shares of common stock on March 16, 2026, at an average price of $22.11 per share. This was a non-discretionary sale to cover tax withholding obligations related to the vesting of performance stock units. Following the transaction, Mehrotra directly holds 555,443 shares of Privia Health common stock.
Privia Health (PRVA) CFO sells 6,391 shares to cover tax obligations
Privia Health's CFO, David Mountcastle, sold 6,391 shares of common stock at $22.11 per share in a non-discretionary transaction. This sale was conducted to cover tax obligations arising from the vesting of performance stock units. Following the sale, Mountcastle still holds a significant number of shares, indicating it was for tax compliance rather than a personal investment decision.
Implied Volatility Spikes in Privia Health Equity Options
Recent options market activity for Privia Health Group (PRVA) shows a significant spike in implied volatility, especially for the May 15, 2026 $22.50 Call option. This suggests traders anticipate notable price movements in the stock, which is further supported by a Zacks Rank #2 (Buy) and positive analyst sentiment. The article suggests this heightened implied volatility could present an opportunity for experienced options traders to sell premium.
Implied Volatility Surging for Privia Health Stock Options
Implied volatility for Privia Health Group, Inc. (PRVA) stock options is surging, particularly for the May 15, 2026 $22.50 Call, indicating that the market expects a significant price move. Analysts currently rate Privia Health as a Zacks Rank #2 (Buy) and have recently increased their earnings estimates for the company. This heightened implied volatility, combined with a positive analyst outlook, suggests a potential trading opportunity in the options market.
Parth Mehrotra reports multiple March sales of PRVA (NASDAQ: PRVA)
Parth Mehrotra, an insider at Privia Health Group, Inc. (NASDAQ: PRVA), has reported multiple sales of common stock in March 2026 through a Form 144 filing. The filing details five separate sales transactions between March 6 and March 13, totaling over 138,000 shares for approximately $3.1 million, alongside a restricted stock vesting event. These transactions are considered routine, with the filing providing gross amounts but not specifying net proceeds or the nature of the trades.
Privia Health Group, Inc. $PRVA Position Lessened by Cinctive Capital Management LP
Cinctive Capital Management LP significantly reduced its stake in Privia Health Group, Inc. (NASDAQ:PRVA) by 92.5% in the third quarter. This move comes as institutional ownership remains high at 94.48%, despite recent insider selling by the CEO and CFO. Analysts maintain a "Moderate Buy" rating with a consensus target price of $31.00, following Privia Health's beat on Q3 EPS and revenue estimates.
Privia Health Group, Inc. SEC Filing
This SEC Form 144 filing from Privia Health Group, Inc. (PRVA) reports planned/resumed sales of common stock and recent dispositions by an affiliated holder. It details a restricted stock vesting delivery of 6,391 shares as compensation on March 13, 2026, and lists multiple sales by David Mountcastle between February and March 2026, including share quantities and proceeds. The filing also provides issuer and securities information, indicating a neutral impact and sentiment.
[Form 4] Privia Health Group, Inc. Insider Trading Activity
Privia Health Group, Inc.'s CEO, Parth Mehrotra, reported two "sell-to-cover" transactions of company common stock on March 12 and March 13, 2026. These sales, totaling 53,992 shares, were specifically to satisfy tax withholding obligations related to performance stock unit vesting and were not discretionary portfolio moves. Following these transactions, Mehrotra directly holds 581,952 shares.
Privia Health (PRVA) CFO mounts 13,018-share tax sell-to-cover in Form 4
Privia Health's CFO, David Mountcastle, sold a total of 13,018 shares of company stock in two transactions on March 12 and 13, 2026. These sales were identified as non-discretionary "sell-to-cover" transactions, executed specifically to meet tax withholding obligations arising from the vesting of performance stock units. Following these transactions, Mountcastle continues to directly hold 226,804 shares and indirectly holds 8,695 shares through his spouse.
Insider Selling: Privia Health Group (NASDAQ:PRVA) CEO Sells 27,229 Shares of Stock
Privia Health Group's CEO, Parth Mehrotra, sold 27,229 shares of company stock for over $585,000, reducing his ownership by 4.47%. This recent sale follows several other transactions by Mehrotra earlier in March. The company's stock has seen a slight increase, and analysts currently rate it as a "Moderate Buy" with an average target price of $31.00.
David Mountcastle Sells 6,453 Shares of Privia Health Group (NASDAQ:PRVA) Stock
Privia Health Group (NASDAQ:PRVA) CFO David Mountcastle recently sold 6,453 shares of the company's stock for $141,320.70. This transaction, along with several other sales in late February and early March, reduced his ownership by 2.69%. The article also details the company's recent stock performance, strong quarterly earnings, institutional trading activity, and analyst ratings, which currently average a "Moderate Buy."
David Mountcastle Sells 6,565 Shares of Privia Health Group (NASDAQ:PRVA) Stock
Privia Health Group (NASDAQ:PRVA) CFO David Mountcastle sold 6,565 shares of the company's stock on March 13th for a total of $141,278.80, reducing his position by 2.81%. This transaction is part of several recent sales by Mountcastle in March and late February. The article also provides an update on Privia Health Group's stock performance, recent earnings, institutional investor activity, and analyst ratings, noting a "Moderate Buy" consensus.
ArrowMark Colorado Holdings LLC Makes New Investment in Privia Health Group, Inc. $PRVA
ArrowMark Colorado Holdings LLC has acquired a new stake of 351,400 shares in Privia Health Group, Inc. (NASDAQ:PRVA) for approximately $8.75 million. This investment makes ArrowMark Colorado Holdings LLC a significant institutional holder, owning about 0.29% of the company. The article also details recent insider stock sales, analyst ratings, and the company's financial performance.
Algert Global LLC Increases Holdings in Privia Health Group, Inc. $PRVA
Algert Global LLC significantly increased its stake in Privia Health Group, Inc. (NASDAQ: PRVA) by 277.4% in the third quarter, now owning 484,304 shares valued at $12.06 million. Other institutional investors also adjusted their holdings, while analysts maintain a "Moderate Buy" consensus rating with an average price target of $31.00. The article also notes recent insider selling by the company's EVP and CEO, totaling over $1 million, despite the company topping quarterly earnings estimates.
Mountcastle sells multiple PRVA share blocks (NASDAQ: PRVA)
David Mountcastle, an insider at Privia Health Group, Inc. (NASDAQ: PRVA), reported multiple sales of Common Stock under Rule 144. These dispositions occurred on various dates in late February and early March 2026, totaling numerous shares and significant dollar amounts. The sales include a substantial transaction on March 12, 2026, for 6,453 shares valued at over $141,000.
Mehrotra Parth, Privia Health CEO, sells $479k in PRVA stock
Privia Health CEO Parth Mehrotra sold 21,097 shares of common stock for approximately $479,112 on March 10, 2026, under a pre-arranged trading plan, while also acquiring over 313,000 shares through restricted and performance stock units. This transaction occurred as the stock experienced a slight downturn, despite InvestingPro analysis suggesting it is undervalued and analysts maintaining positive outlooks following strong Q4 2025 results.
Privia Health Group opens hiring for Sales Growth Director in Nashville to expand physician partnerships
Privia Health Group is seeking a Sales Growth Director in Nashville to strengthen
Parth Mehrotra sells shares at PRVA (NASDAQ: PRVA) — Form 144 notice
Parth Mehrotra, an insider at Privia Health Group, Inc. (NASDAQ: PRVA), reported sales of common stock through Form 144 filings. The sales involved 21,440 shares on March 6, 2026, 41,999 shares on March 9, 2026, and 21,097 shares on March 10, 2026. Additionally, a restricted stock vesting of 26,763 shares occurred on March 11, 2026.
Mehrotra Parth, Privia Health CEO, sells $479k in PRVA stock By Investing.com
Privia Health CEO Mehrotra Parth sold 21,097 shares of common stock for approximately $479,112 on March 10, 2026, under a pre-arranged trading plan. Despite this sale, Mehrotra acquired over 313,000 shares through restricted and performance stock units. Privia Health has shown strong financial performance in Q4 2025, exceeding revenue and EPS forecasts, leading to positive analyst ratings and price target increases from Jefferies and Piper Sandler.
Privia Health (PRVA) EVP awarded 28,268 restricted stock units
Privia Health Group, Inc. (PRVA) announced that its Executive Vice President and General Counsel, Edward C. Fargis, was awarded 28,268 restricted stock units (RSUs). These RSUs, granted under the 2021 Omnibus Incentive Plan, have no cash cost and will vest in substantially equal annual installments over three years, contingent on Fargis's continued service. Following this transaction, Fargis directly holds 111,979 shares of common stock.
Insider Sell: Parth Mehrotra Sells Shares of Privia Health Group Inc (PRVA)
Parth Mehrotra, CEO of Privia Health Group Inc (PRVA), sold 21,097 shares on March 10, 2026, bringing his total ownership to 635,944 shares. This transaction is part of a pattern over the last year with 14 insider sells and no buys. Despite a high P/E ratio compared to the industry median, the stock is considered modestly undervalued with a price-to-GF-Value ratio of 0.84 based on GuruFocus' intrinsic value estimate.
Privia Health CEO Sells Over $479K in Shares
Parth Mehrotra, CEO of Privia Health Group, sold 84,536 shares of the company's stock over the past week for over $1.9 million. Despite the sale, Mehrotra still retains a significant stake valued at approximately $7.3 million. While insider selling can signal various things, investors are advised to consider the company's broader context and long-term prospects.
Privia Health Group (NASDAQ:PRVA) CEO Parth Mehrotra Sells 21,097 Shares
Privia Health Group (NASDAQ:PRVA) CEO Parth Mehrotra sold 21,097 shares on March 10th for over $479,000, reducing his stake by 6.14% to 322,698 shares. This sale is part of a larger transaction where he sold 84,536 shares between March 6-10 for approximately $1.94 million. Despite the insider selling, analysts maintain a "Moderate Buy" rating for PRVA with a consensus target price of $31.00, following a recent earnings beat and 17.4% year-over-year revenue growth.
